GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$15.71
+0.99 (+6.73%)
Open$14.92
Previous Close$14.72
Day High$16.04
Day Low$14.88
52W High$25.77
52W Low$3.50
Volume—
Avg Volume915.7K
Market Cap1.29B
P/E Ratio61.35
EPS$0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+144.7% upside
Current
$15.71
$15.71
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 81.92M | 401.98M | 400.93M |
| Net Income | -78,752,439 | -29,192,444 | -34,329,564 |
| Profit Margin | -96.1% | -7.3% | -8.6% |
| EBITDA | -79,072,701 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |